Welcome to our dedicated page for Alnylam Pharmaceuticals SEC filings (Ticker: ALNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech filings can feel like decoding a laboratory notebook. Alnylam Pharmaceuticals’ RNAi pipeline spans rare-disease trials, partnership milestones, and intricate cash-flow disclosures—details scattered across hundreds of pages. If you’ve searched for “Alnylam SEC filings explained simply” or wondered how to spot pivotal RNAi data buried in its 10-K, you’re not alone.
Stock Titan solves that problem in minutes. Our AI parses every Alnylam quarterly earnings report 10-Q filing, tags key metrics like cash runway, and delivers real-time alerts on Alnylam Form 4 insider transactions—so you never miss a chief scientist’s stock move. Need the Alnylam annual report 10-K simplified? We highlight pipeline progress, collaboration revenue, and patent cliffs. Curious about “Alnylam 8-K material events explained”? We translate FDA designations, partnership amendments, and trial readouts into plain English. From Alnylam executive stock transactions Form 4 to the proxy statement executive compensation tables, all documents stream directly from EDGAR with instant AI summaries.
Use cases investors rely on:
- Monitor Alnylam insider trading Form 4 transactions before material announcements
- Compare RNAi program spending across each Alnylam earnings report filing analysis
- Review Alnylam proxy statement executive compensation to gauge R&D incentives
- Track Alnylam quarterly earnings report 10-Q filing for clinical-trial cash needs
- Receive Alnylam Form 4 insider transactions real-time for sentiment signals
Understanding Alnylam SEC documents with AI means faster decisions based on the disclosures that actually move a biotech stock.
ALNYLAM PHARMACEUTICALS, INC. (ALNY) Form 3 filed for Bryan Supran, who is identified as Executive Vice President, Chief Legal Officer and Secretary. The event date requiring the statement is 09/15/2025. The filing states that no securities are beneficially owned by the reporting person and attaches Exhibit 24 (Power of Attorney). The form is signed by an attorney-in-fact on behalf of Mr. Supran on 09/22/2025.
Colleen F. Reitan, an Alnylam Pharmaceuticals director, reported multiple transactions on 09/09/2025 under a Rule 10b5-1(c) plan adopted June 10, 2025. She exercised a stock option to buy 18,000 shares at an exercise price of $100.65 and subsequently sold incremental blocks of common stock in multiple transactions at weighted-average prices ranging from $456.93 to $479.90. Following the reported trades, she directly beneficially owns 775 shares and holds options covering 18,000 shares exercisable through 06/01/2028. The filing was signed by her attorney-in-fact on 09/11/2025.
Alnylam Pharmaceuticals, Inc. filed an 8-K reporting a material event related to a Convertible Note Offering. The filing references press releases issued on The submission also notes inclusion of the cover page interactive data file in Inline XBRL and is signed by Jeffrey V. Poulton, Executive Vice President and Chief Financial Officer. The filing does not disclose terms, amounts, or use of proceeds for the convertible notes within the provided text.
Alnylam Pharmaceuticals (ALNY) notice reports a proposed sale of 18,000 shares of common stock through UBS Financial Services on the NASDAQ, with an aggregate market value of $8,300,070.00 and 131,079,015 shares outstanding. The securities were acquired and are proposed to be sold on 09/09/2025 via exercise of stock options from the issuer, with cash payment recorded. The filer reports no securities sold in the past three months. The form includes the standard representation that the seller is not aware of undisclosed material adverse information and references Rule 10b5-1 plan adoption if applicable.
Tolga Tanguler, EVP and Chief Commercial Officer of Alnylam Pharmaceuticals (ALNY), reported multiple open-market sales of Company common stock on 08/29/2025 executed under a Rule 10b5-1 trading plan. The filings show six separate sale transactions totaling 3,474 shares, with weighted average sale prices reported in ranges from approximately $445.32 to $452.54 per share. Following these transactions the reporting person’s beneficial ownership is reported as 25,992 shares. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Tanguler and includes explanatory notes that each reported price is a weighted average of multiple executions within the stated ranges.
Form 144 filing for Alnylam Pharmaceuticals (ALNY) discloses a proposed sale of 3,474 shares of Common stock through UBS Financial Services on NASDAQ with an aggregate market value of $1,571,012 and 131,079,015 shares outstanding. The securities were acquired as performance stock units: 1,673 shares on 06/24/2024 and 1,801 shares on 04/26/2023, with payment dates matching acquisition dates. The filer reports Nothing to Report for securities sold in the past three months and includes the customary representation that they do not possess undisclosed material adverse information. The notice is procedural under Rule 144 to report an intended sale.
Pushkal Garg, Executive Vice President & Chief R&D Officer of Alnylam Pharmaceuticals (ALNY), reported transactions on Form 4 showing issued and subsequent sales of common stock tied to performance-based awards and a Rule 10b5-1 plan.
On 08/15/2025, 2,851 shares were issued upon vesting of 30% of a performance-based stock unit awarded 03/01/2024 after the company met a clinical milestone. Between 08/18/2025 and 08/19/2025 the reporting person sold multiple tranches of shares under a previously adopted 10b5-1 trading plan, at weighted-average prices ranging from about $447.98 to $461.74. Following these transactions, Garg directly owned 20,221 shares and indirectly held 431 shares via a managed account and 250 shares in a trust.
Tolga Tanguler, EVP & Chief Commercial Officer of Alnylam Pharmaceuticals (ALNY), reported changes in beneficial ownership related to a performance-based award and subsequent sell-to-cover transactions. On 08/15/2025 Tanguler received 2,851 shares that vested from a performance-based stock unit granted on 03/01/2024 after achievement of a clinical milestone. Following the vesting, a series of automatic sales executed on 08/18/2025 sold varying blocks of shares to satisfy statutory tax withholding, with weighted-average sale prices reported in ranges from $447.53 up to $456.00 per share. After these transactions Tanguler beneficially owned 29,466 shares.
Jeffrey V. Poulton, EVP and Chief Financial Officer of Alnylam Pharmaceuticals (ALNY), received and sold shares following the vesting of performance-based stock units. A PSU tranche vested on 08/15/2025 after the Compensation Committee determined a clinical milestone was achieved, resulting in the issuance of 4,644 shares to Mr. Poulton. Between 08/18/2025 the reporting person had multiple automatic sales of shares to satisfy mandatory tax-withholding obligations at weighted-average prices in the $447.53–$456.00 range. The filing also notes 57 shares held indirectly via a managed account from the company 401(k) match.
Yvonne Greenstreet, Director and CEO of Alnylam Pharmaceuticals (ALNY), reported a mix of equity activity tied to performance compensation and tax withholding on vested awards. On 08/15/2025 she received 14,252 shares upon vesting of 30% of a performance-based stock unit awarded 03/01/2024 after a clinical milestone determination. Following that vesting, multiple automatic sales occurred on 08/18/2025 to satisfy mandatory sell-to-cover tax withholding, reducing her direct holdings from 63,200 to 56,221 shares. The filing also shows 407 shares held indirectly via a managed account and shares acquired under the company 401(k) matching program.
FAQ
What is the current stock price of Alnylam Pharmaceuticals (ALNY)?
What is the market cap of Alnylam Pharmaceuticals (ALNY)?
